Stefan Symeonides

Filter

2021
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study
Choueiri, T., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y., Hajek, J., Symeonides, S. N., Lee, J. L., Sarwar, N., Thiery-vuillemin, A., Gross-goupil, M., Mahave, M., Haas, N., Sawrycki, P., Zhang, P., Imai, K., Willemann-rogerio, J., Quinn, D. & Powles, T., 16 Jun 2021, (E-pub ahead of print).
Research output: Contribution to conference › Abstract › peer-review

Research output